BeiGene Ltd. (BGNE)
| Market Cap | 28.71B |
| Revenue (ttm) | 862.69M |
| Net Income (ttm) | -1.17B |
| Shares Out | 91.80M |
| EPS (ttm) | -13.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 18 |
| Last Price | $336.68 |
| Previous Close | $323.67 |
| Change ($) | 13.01 |
| Change (%) | 4.02% |
| Day's Open | 324.92 |
| Day's Range | 324.33 - 337.85 |
| Day's Volume | 48,934 |
| 52-Week Range | 155.16 - 388.97 |
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene reported recent business highlights, anticipated upcoming milestones, and financial results for the first quarter of 2021.
BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against Johnson & Johnson's (NYSE: JNJ) Imbruvica (ibr...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene announces positive interim results in Phase 3 ALPINE trial comparing BRUKINSA® (zanubrutinib) to ibrutinib in chronic lymphocytic leukemia.
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...
BeiGene Ltd (NASDAQ: BGNE) has announced data from Phase 2 trial evaluating Brukinsa (zanubrutinib) in hospitalized COVID-19 patients, requiring supplemental oxygen without mechanical ventilation. The s...
MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines ...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines, tod...
In Amgen Inc.'s (NASDAQ:AMGN) recent agreement to buy small cancer drug developer Five Prime Therapeutics Inc. (NASDAQ:FPRX) for nearly $2 billion, there seems to be a message for investors in other sma...
Hutchison China MediTech (NASDAQ: HCM) has initiated a Phase 1b/2 study of surufatinib combined with BeiGene Ltd's (NASDAQ: BGNE) tislelizumab in patients with advanced solid tumors in the U.S. and Euro...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...
Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
The stock price of BeiGene, a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a 10% drop over the last ten trading days, while it's down 6%...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces Closing of Collaboration with Novartis to Develop & Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe ...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...
BOSTON & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 ...
The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application seeking approval for BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström's Macrog...
CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström's Macroglobulinemia
Week In Review: Matridx Raises $32 Million For AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
HEMEL HEMPSTEAD, England & BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Applicati...
BeiGene out-licensed ex-China rights for tislelizumab, its China-approved anti-PD-1 antibody, to Novartis in a $2.2 billion agreement. Inmagene in-licensed global rights to four novel pre-clinical immun...
BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.
Beigene stock broke out and surged to a record high Thursday after China's regulators approved its lung cancer treatment. Earlier this week, Novartis signed on to commercialize the drug.
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene's anti-PD-1 antibody received approval in China in first-line advanced squamous non-small cell lung cancer.
Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.
BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and commercialize Anti-PD-1 antibody Tislelizumab. BeiG...
Beigene stock jumped Tuesday on a cancer drug development deal with Novartis worth up to $2.2 billion, as Vir Biotechnology also announced a hepatitis B tie-up with Gilead Sciences. The post Beigene Sur...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Novartis enter into a collaboration to develop, manufacture and commercialize tislelizumab, BeiGene's anti-PD-1 antibody.
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--Strand Therapeutics and BeiGene entered an option and license agreement aimed at developing, commercializing Strand's mRNA treatments for sol...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative m...
BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces inclusion of three innovative oncology products in China National Reimbursement Drug List (NRDL).
Trial Represents First-Ever Phase 0 for Newly Diagnosed Patients with Glioblastoma Trial Represents First-Ever Phase 0 for Newly Diagnosed Patients with Glioblastoma
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces that BLINCYTO® (blinatumomab) for injection has been approved in China in relapsed/refractory B-cell precursor ALL.
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene announces clinical data on BTK inhibitor BRUKINSA (zanubrutinib) in B-cell malignancies and Waldenström's at the 62nd ASH annual mee...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene presents data on BTK inhibitor BRUKINSA in marginal zone lymphoma and chronic lymphocytic leukemia at the 62nd ASH Annual Meeting.
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative m...
BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (SREs) in pa...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces the second approval of XGEVA® (denosumab) in China.
Pharmaceuticals is the only sector that has all three characteristics foreign investors are looking for in Chinese investments: an industry that will consolidate, pro-growth policy reform and support an...
CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BGNE--Global Phase 3 trial of tislelizumab in second- or third-line non-small cell lung cancer met the primary endpoint at interim analysis.
About BGNE
BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA... [Read more...]
| Industry Biotechnology | IPO Date Feb 3, 2016 |
| CEO John Oyler | Employees 5,400 |
| Stock Exchange NASDAQ | Ticker Symbol BGNE |
Financial Performance
In 2020, BeiGene's revenue was $308.87 million, a decrease of -27.87% compared to the previous year's $428.21 million. Losses were -$1.60 billion, 68.3% more than in 2019.
Analyst Forecasts
According to 19 analysts, the average rating for BeiGene stock is "Buy." The 12-month stock price forecast is 361.36, which is an increase of 7.33% from the latest price.